Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891876 | 0.84 | HRH3 (0.37) | HRH3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL30085037 | 0.84 | HRH3 (0.40) | HRH3 | |
| SCHEMBL16480467 | 0.83 | HRH3 (0.55) | HRH3 | |
| SCHEMBL16194551 | 0.81 | HSD17B10 (0.42) | HRH3SMN1; SMN2HSD17B10 | |
| SCHEMBL15025236 | 0.81 | HSD17B10 (0.42) | HRH3SMN1; SMN2HSD17B10 | |
| SCHEMBL9893052 | 0.81 | TERT (0.41) | HRH3MEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL9892347 | 0.79 | HRH3 (0.39) | HRH3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL24926280 | 0.73 | HTT (0.37) | HRH3 | |
| SCHEMBL22541505 | 0.73 | TACR1 (0.38) | HRH3ALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL12014400 | 0.72 | ALDH1A1 (0.48) | MEN1ALDH1A1MAPTKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | HRH3 236/4885MEN1 4874/4885ALDH1A1 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.